Business Wire

REPLY

15.2.2024 09:31:25 CET | Business Wire | Press release

Share
REPLY: C&A Collaborates With Up Reply to Increase Sales Through a Targeted Onsite Personalisation Strategy in Online Retailing

Up Reply, the agency of the Reply Group specialised in optimising customer experiences, is supporting the international fashion retailer C&A to implement targeted onsite personalisation with a predicted increase in sales of 2.5%. This positive development is the result of an innovative strategy focused on customer-centric online shopping to improve the overall shopping experience, increase purchase frequency and sustainably strengthen customer loyalty.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215456573/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Thanks to an optimized customer journey, C&A is now benefiting from a forecast sales increase. This is made possible by a personalization strategy from the experts at Up Reply. (Photo: Business Wire)

The basis for success is a personalised customer journey designed by Up Reply, which offers customers a tailored, seamless shopping experience on the website. Customised content and offers encourage users to visit the website, even without a specific purchase intent, and provide optimal support for product research and selection.

Up Reply relies on the implementation of the Dynamic Yield platform, the establishment of a "Centre of Excellence" and A/B tests to deliver a personalised shopping experience in the C&A web shop. Dynamic Yield was used to create campaign templates to standardise content along the customer journey. The "Centre of Excellence" distributes responsibilities and ensures that the personalisation strategy can be implemented smoothly. Continuous A/B testing helps to evaluate the relevance of products or recommendations.

Dr Corinna Ogonowski, Lead User Research & Experimentation at C&A, summarised: "Up Reply is a good partner for scaling personalisation and A/B testing programmes. With their strategic and operational support, we were able to take our programme to a new level in a short period of time. We have achieved very good results in optimising the user experience and supporting our growth. I would particularly like to highlight their technical expertise with Dynamic Yield and other platforms."

Up Reply also attaches particular importance to the use of automation solutions. The aim of these measures is to increase the average order value and reduce the return rate. In order to tap into new growth potential, marketing campaigns have been automated and the internationalisation of the personalisation strategy has been driven forward.

The benefits of personalised content go beyond a better customer experience and offer retailers clear advantages. These include increased customer engagement, higher purchase frequency, lower return rates, increased referrals that lead to lasting customer relationships and ultimately higher sales.

Roman Goedeke, Reply Executive Partner, commented: "With our user-centric catalogue of actions, we were able to help C&A achieve the predicted increase in sales. This project underlines the importance of targeted onsite personalisation with a coherent strategy for sustainable business impact and demonstrates how Up Reply strengthens customer engagement and loyalty, reduces acquisition costs and increases marketing ROI through innovative strategies and technologies."

Reply

Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Up Reply

Up Reply is the Reply Group company specialising in digital growth and experience optimisation. The experts provide international clients with data-driven methods for personalisation of digital channels, A/B testing, and analytics across the entire customer journey. The result is user-centered experiences that contribute to the business objectives. Up Reply supports with strategy consulting, onboarding and offers full service with tools such as Dynamic Yield, Optimizely, Adobe Target or Adobe Analytics, Google Analytics and Contentsquare. upreply.de/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215456573/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye